Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
A650330-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$150.90
|
|
|
A650330-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$250.90
|
|
|
A650330-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$500.90
|
|
|
A650330-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$750.90
|
|
| Synonyms | 1H-Pyrazol-5-ol, 3-phenyl-4-propyl-1-(2-pyridinyl)-, hydrochloride (1:1) | HY-120801 | 1395946-75-4 | Apx 115 | Q99G5ZE5U5 | APX 115 [WHO-DD] | Isuzinaxib hydrochloride | SCHEMBL15610231 | UNII-Q99G5ZE5U5 | 5-phenyl-4-propyl-2-pyridin-2-yl-1H-pyrazol-3-on |
|---|---|
| Specifications & Purity | ≥99% |
| Biochemical and Physiological Mechanisms | APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1 , Nox2 and Nox4 , respectively. APX-115 effectively prevents kidney injury. |
| Storage Temp | Store at 2-8°C,Desiccated |
| Shipped In |
Wet ice This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1 , Nox2 and Nox4 , respectively. APX-115 effectively prevents kidney injury In Vitro APX-115 (5?μM; 60?min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression in the mouse podocyte cell line. ?\nIn the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo APX-115 (oral gavage; 60?mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice. ?\nAPX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Six-week-old male diabetic db/db mice (C57BLKS/J- lepr db /lepr db )Dosage: 60 mg/kg Administration: Oral gavage; per day; for 12 weeks Result: Significantly improved insulin resistance in diabetic mice. Form:Solid IC50& Target:NOX1 NOX2 NOX4 |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Pyridines and derivatives |
| Subclass | Pyrazolylpyridines |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Pyrazolylpyridines |
| Alternative Parents | Methylpyridines Benzene and substituted derivatives Vinylogous amides Pyrazolines Pyrazoles Heteroaromatic compounds Lactams Propargyl-type 1,3-dipolar organic compounds Carboxylic acids and derivatives Azacyclic compounds Aldimines Organopnictogen compounds Organooxygen compounds Organic oxides Hydrochlorides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | 2-pyrazolylpyridine - Methylpyridine - Benzenoid - Monocyclic benzene moiety - Heteroaromatic compound - Vinylogous amide - Pyrazoline - Pyrazole - Azole - Lactam - Azacycle - Organic 1,3-dipolar compound - Propargyl-type 1,3-dipolar organic compound - Carboxylic acid derivative - Aldimine - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Hydrochloride - Organooxygen compound - Organonitrogen compound - Imine - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as pyrazolylpyridines. These are compounds containing a pyrazolylpyridine skeleton, which consists of a pyrazole linked (not fused) to a pyridine by a bond. |
| External Descriptors | Not available |
|
|
|
| IUPAC Name | 5-phenyl-4-propyl-2-pyridin-2-yl-1H-pyrazol-3-one;hydrochloride |
|---|---|
| INCHI | InChI=1S/C17H17N3O.ClH/c1-2-8-14-16(13-9-4-3-5-10-13)19-20(17(14)21)15-11-6-7-12-18-15;/h3-7,9-12,19H,2,8H2,1H3;1H |
| InChIKey | YEEIHSUMLNXRMI-UHFFFAOYSA-N |
| Smiles | CCCC1=C(NN(C1=O)C2=CC=CC=N2)C3=CC=CC=C3.Cl |
| Isomeric SMILES | CCCC1=C(NN(C1=O)C2=CC=CC=N2)C3=CC=CC=C3.Cl |
| Alternate CAS | 1395946-75-4 |
| PubChem CID | 60172240 |
| MeSH Entry Terms | 3-phenyl-1-(pyridin-2-yl)-4-propyl-1H-5-hydroxypyrazole HCl;3-phenyl-4-propyl-1-(2-pyridinyl)-1H-pyrazol-5-ol;3-phenyl-4-propyl-1-(2-pyridinyl)-1H-pyrazol-5-ol hydrochloride;APX-115;APX-115 free base;Ewha-18278;EWHA-18278 free base;isuzinaxib;isuzinaxib h |
| Molecular Weight | 315.80 |
| Solubility | DMSO : 100 mg/mL (316.66 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 315.800 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 315.114 Da |
| Monoisotopic Mass | 315.114 Da |
| Topological Polar Surface Area | 45.200 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 412.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |